Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has a higher price-to-earnings ratio of 21.88x compared to its average ratio. ACAD has 36-month beta value of 0.37. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 6 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for ACAD is 164.30M, and currently, short sellers hold a 6.52% ratio of that float. The average trading volume of ACAD on January 15, 2025 was 2.30M shares.
ACAD) stock’s latest price update
Acadia Pharmaceuticals Inc (NASDAQ: ACAD)’s stock price has decreased by -5.59 compared to its previous closing price of 17.90. However, the company has seen a -3.21% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-01-14 that SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company’s CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2025 is shaping up to be an exciting year as we build on the success of our two growing brands, NUPLAZID and DAYBUE, which together are proj.
ACAD’s Market Performance
Acadia Pharmaceuticals Inc (ACAD) has experienced a -3.21% fall in stock performance for the past week, with a -6.22% drop in the past month, and a 13.27% rise in the past quarter. The volatility ratio for the week is 4.98%, and the volatility levels for the past 30 days are at 4.32% for ACAD. The simple moving average for the last 20 days is -2.79% for ACAD stock, with a simple moving average of 3.13% for the last 200 days.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Guggenheim repeating the rating for ACAD by listing it as a “Neutral.” The predicted price for ACAD in the upcoming period, according to Guggenheim is $20 based on the research report published on January 03, 2025 of the current year 2025.
Morgan Stanley gave a rating of “Equal-Weight” to ACAD, setting the target price at $20 in the report published on August 07th of the previous year.
ACAD Trading at -0.47% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.30% of loss for the given period.
Volatility was left at 4.32%, however, over the last 30 days, the volatility rate increased by 4.98%, as shares sank -2.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.42% upper at present.
During the last 5 trading sessions, ACAD fell by -3.21%, which changed the moving average for the period of 200-days by -7.14% in comparison to the 20-day moving average, which settled at $17.39. In addition, Acadia Pharmaceuticals Inc saw -7.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Teehan Brendan, who sale 10,329 shares at the price of $16.81 back on Nov 19 ’24. After this action, Teehan Brendan now owns 62,105 shares of Acadia Pharmaceuticals Inc, valued at $173,630 using the latest closing price.
Kihara James, the PRINCIPAL ACCOUNTING OFFICER of Acadia Pharmaceuticals Inc, sale 4,073 shares at $16.81 during a trade that took place back on Nov 19 ’24, which means that Kihara James is holding 19,863 shares at $68,467 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.14. The total capital return value is set at 0.18. Equity return is now at value 27.36, with 15.97 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 4.11.
Currently, EBITDA for the company is -67.83 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 2.91. The receivables turnover for the company is 9.46for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.29.
Conclusion
To put it simply, Acadia Pharmaceuticals Inc (ACAD) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
